This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Psoriasis
  • /
  • Brodalumab: an evidence-based review of its potent...
Journal

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis

Read time: 1 mins
Published:21st Jul 2014
Author: Coimbra S, Figueiredo A, Santos-Silva A.
Source: Core Evidence
Availability: Free full text
Ref.:Core Evid. 2014 Jul 21;9:89-97.
DOI:10.2147/CE.S33940
Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis

Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis.


Read abstract on library site    Access full article